New Delhi: The World Health Organization (WHO) has decided to resume the clinical trials of anti-malarial drug Hydroxychloroquine for treating COVID-19 patients.
The initial trials will be conducted on over 3,500 patients in more than 35 countries.
Based on a report published in The Lancet medical journal, the health body had temporarily stopped the trials.
“Last week, the executive group of the Solidarity Trial (includes hundreds of hospitals across the world) decided to implement a temporary pause of the hydroxychloroquine arm of the trial, because of concerns raised about the safety of the drug,” WHO chief Tedros Adhanom Ghebreyesus told the media.
“On the basis of the available mortality data, the members of the committee recommended that there are no reasons to modify the trial protocol,” he added.
Besides, the group will keep a close watch on the trials being conducted to ensure safety of all the patients.
Also Read: Corona Alert: Vaccine Likely By Sept-Oct, Says World Health Expert
